In this episode, we interview Dr. Ethan Perlstein, founder and CEO of Curetopia, about his mission to end rare genetic diseases. Dr. Perlstein shares his journey as a scientist, builder, and investor, and discusses Curetopia's innovative approach to drug development, including the use of blockchain and Web3 technologies. He emphasizes the urgency of addressing rare diseases and the need for new models to accelerate the search for cures.

Chapters/Timestamps:

• 00:00 - Introduction and Dr. Ethan Perlstein's Background
• 08:50 - The Challenge of Rare Diseases
• 21:25 - Curetopia's Mission and Approach
• 31:54 - Blockchain and the Future of Drug Development
• 40:09 - The Future of Curetopia and Rare Disease Research

Guest Information:

• Guest's Name: Dr. Ethan Perlstein
• Guest's Title/Position: Founder and CEO
• Company/Affiliation: Curetopia
• Guest's Bio: Dr. Ethan Perlstein is a scientist, builder, and investor with a focus on developing cures for rare genetic diseases. He is the founder and CEO of Curetopia, a company utilizing innovative approaches to drug development and funding.

Links and Resources:

• Curetopia Website: https://www.curetopia.xyz/
• Curetopia on Telegram: https://t.me/curetopia
• Curetopia on X (Twitter): https://x.com/endrarediseases

Key Takeaways/Highlights:

• Dr. Perlstein's background as a scientist and his transition into building and investing in biotech companies.
• The challenges and misconceptions surrounding rare diseases, including their prevalence and the lack of financial incentive for research.
• Dr. Perlstein's motivation for focusing on rare diseases, inspired by his interaction with parents of affected children.
• Curetopia's mission to end rare diseases through innovative drug development strategies.
• The potential of blockchain and Web3 technologies to transform drug development, including funding, data sharing, and community engagement.
• Dr. Perlstein's vision for a more collaborative and accelerated approach to finding cures for rare diseases.